Biomea Fusion Inc (NASDAQ: BMEA) released preliminary topline data from its ongoing Phase 1 COVALENT-101 trial, showcasing initial responses in relapsed/refractory AML patients with
Initial topline data from COVALENT-101 trial revealed 2 complete responses (CRs) out of 5 relapsed/refractory AML patients carrying menin-dependent mutations treated at Dose Level 4
Dose Level 4 exposure correlates
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining more than 50 points on Monday.
The Dow traded up 0.18% to 33,788.05 while the NASDAQ fell 0.61% to 13,410.63. The S&P 500, also fell, dropping, 0.11% to 4,343.41.
Gainers
Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy.
U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 80 points on Monday.
The Dow traded down 0.02% to 33,719.54 while the NASDAQ fell 0.53% to 13,420.67. The S&P 500, also fell, dropping, 0.19% to 4,340.11.
Biomea Fusion Inc (NASDAQ: BMEA) announced the presentation of new clinical data from the first two cohorts from the Phase 2 portion of its ongoing Phase 1/2 clinical study (COVALENT-111) of BMF-219 in